FDA Approves MicroLight Cold Laser for Carpal Tunnel Syndrome
HOUSTON, Feb. 12 -- MicroLight Corp. of America said it has won market clearance from the Food and Drug Administration for its ML830 Cold Laser for use in the nonsurgical treatment and management of carpal tunnel syndrome (CTS).
"FDA market clearance for the ML830 resulted from working with FDA examiners over the past ten years to ensure continuing compliance with the law," said Mike Barbour, MicroLight president. "Our ML830 successfully performed in several double-blind studies and in many clinical trials where some rather substantial parties were involved, including Baylor College of Medicine and General Motors," he added.
LATEST NEWS
- Exail Signs LLNL Contract, Partners with Eelume
Apr 26, 2024
- Menlo Moves U.S. HQ: Week in Brief: 4/26/2024
Apr 26, 2024
- Optofluidics Platform Keys Label-, Amplification-Free Rapid Diagnostic Tool
Apr 25, 2024
- DUV Lasers Made with Nonlinear Crystals Enhance Lithography Performance
Apr 25, 2024
- Teledyne e2v, Airy3D Collaborate on 3D Vision Solutions
Apr 24, 2024
- One-Step Hologram Generation Speeds 3D Display Creation
Apr 24, 2024
- Innovation Award Winners for Laser Technology Honored in Aachen
Apr 23, 2024
- Intech 2024: AI Arrives on the Shop Floor
Apr 22, 2024